DWTX Dogwood Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818844 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.1%
TTM EPS YoY140.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-70.5%
ROA-30.0%
ROIC (approx.)-78.2%
Asset turnover—
Leverage & solvency
Liabilities / assets15.2%
Debt / equity0.00x
Current ratio2.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $21.87M | $3.53M |
| SG&A expense | $6.10M | $8.70M |
| Operating income | -$27.97M | -$12.23M |
| Pretax income | -$34.04M | -$12.35M |
| Income tax | $221,096 | -$503 |
| Net income | -$34.26M | -$12.35M |
| EBITDA | -$27.97M | -$12.22M |
| EPS (basic) | -7.13 | -12.52 |
| EPS (diluted) | -7.13 | -12.52 |
| Weighted avg. shares (diluted) | 4.98M | 1.03M |
| Balance sheet | ||
| Cash & equivalents | $6.52M | $14.85M |
| Current assets | $8.43M | $16.54M |
| PP&E, net | $12,754 | $16,811 |
| Goodwill | $12.40M | $11.81M |
| Intangibles | $68.99M | $65.71M |
| Total assets | $90.17M | $94.31M |
| Current liabilities | $3.06M | $3.18M |
| Total liabilities | $15.27M | $30.03M |
| Shareholders' equity | $74.90M | -$10.12M |
| Shares outstanding | 29.74M | 1.33M |
| Cash flow statement | ||
| Operating cash flow | -$15.62M | -$8.79M |
| Investing cash flow | — | $3.76M |
| Financing cash flow | $7.28M | $16.70M |
| Depreciation & amortization | $2,063 | $12,177 |
| Stock-based compensation | $355,642 | $476,021 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.